MedPath

Efficacy and safety of insulin degludec in Japanese type 2 diabetes

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000011550
Lead Sponsor
Center for Diabetes, Metabolism and Endocrinology, Kansai Electric Power Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

(1)severe ketosis, diabetic coma (2)history of severe hypoglycemia (3)severe renal dysfunction (eGFR <30) and hepatic dysfunction (4)pancreatic deasease, endocrine deasease, taking diabetogenic medication (5)pregnancy (6)unable to self-injection (7)allergy for degludec or glargine (8)judged as ineligible by clinical investigators for some other reasons

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
glucose variability by Continuous Glucose Monitoring System
Secondary Outcome Measures
NameTimeMethod
Frequency of hypoglycemia, Blood glucose plofile measured by SMBG, HbA1c, 1,5-AG, insulin dose
© Copyright 2025. All Rights Reserved by MedPath